337 related articles for article (PubMed ID: 16076699)
1. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
Fowler JF
Acta Oncol; 2005; 44(3):265-76. PubMed ID: 16076699
[TBL] [Abstract][Full Text] [Related]
2. What hypofractionated protocols should be tested for prostate cancer?
Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Fractionation and protraction for radiotherapy of prostate carcinoma.
Brenner DJ; Hall EJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1095-101. PubMed ID: 10192361
[TBL] [Abstract][Full Text] [Related]
5. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
6. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
Sminia P; Schneider CJ; Fowler JF
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of incomplete repair parameters for rat spinal cord: the feasibility of large doses per fraction in PDR and HDR brachytherapy.
Pop LA; Millar WT; Visser AG; van der Kogel AJ
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):215-26. PubMed ID: 11516872
[TBL] [Abstract][Full Text] [Related]
8. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
9. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
10. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
[TBL] [Abstract][Full Text] [Related]
11. A simple method of obtaining equivalent doses for use in HDR brachytherapy.
Nag S; Gupta N
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):507-13. PubMed ID: 10661360
[TBL] [Abstract][Full Text] [Related]
12. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
13. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
14. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
Nahum AE; Movsas B; Horwitz EM; Stobbe CC; Chapman JD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):391-401. PubMed ID: 12957250
[TBL] [Abstract][Full Text] [Related]
15. CT based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses to the rectum and bladder.
Hashim N; Jamalludin Z; Ung NM; Ho GF; Malik RA; Phua VC
Asian Pac J Cancer Prev; 2014; 15(13):5259-64. PubMed ID: 25040985
[TBL] [Abstract][Full Text] [Related]
16. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
17. Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand DH; Brüningk SC; Wilkins A; Fernandez K; Naismith O; Gao A; Syndikus I; Dearnaley DP; Tree AC; van As N; Hall E; Gulliford S;
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):596-608. PubMed ID: 33412260
[TBL] [Abstract][Full Text] [Related]
18. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT).
Wang JZ; Li XA; D'Souza WD; Stewart RD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):543-52. PubMed ID: 12957268
[TBL] [Abstract][Full Text] [Related]
19. Impact of tumor repopulation on radiotherapy planning.
Wang JZ; Li XA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
[TBL] [Abstract][Full Text] [Related]
20. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
